sponsored
PatientsVille.com Logo

PatientsVille

Breast Hyperplasia Medical Research Studies

Up-to-date List of Breast Hyperplasia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Breast Hyperplasia Medical Research Studies

Rank Status Study
1 Not yet recruiting Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
Conditions: Atypical Ductal Breast Hyperplasia;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ
Interventions: Drug: metformin hydrochloride;   Other: placebo
Outcome Measures: Test for the presence or absence of atypia in RPFNA after 12 months and 24 months. Month 24 is optional for the placebo group for those patients who remain on the placebo arm and will not receive metformin (Metformin versus placebo control).;   Test for the Masood Score and the presence of atypia or disapperance of atypia in RPFNA after 12 months (for both arms) and 24 months for Metformin arm.;   Test the reproducibility of RPPM in duplicate RPPM determination from single bilateral RPFNA specimen.;   Determine the change in percent breast density from prior to the initiation of metformin or placebo treatment through therapy (ie, Months 12 and 24) and following therapy (Months 36 and 48).;   Compare Masood Cytology Score value at 0, 12 and 24 months in right and left breast from the same individual in the metformin and non-metformin group.;   Correlate baseline RPPM values with presence of atypia at Month 12 and Month 24.
2 Recruiting Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
Conditions: Atypical Ductal Breast Hyperplasia;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ
Interventions: Dietary Supplement: curcumin;   Other: Biomarker analysis;   Other: Assessment of Dietary Intake;   Other: Daily Log
Outcome Measures: Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin (NEC)in women at high risk for developing breast cancer.;   Evaluate possible correlations between physical factors such as body mass (BMI), dietary intake and pro-inflammatory effects in plasma and breast adipose tissue.
3 Recruiting A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
Conditions: Breast Cancer;   Precancerous Condition
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: Excess human biological tissue;   Procedure: quality-of-life assessment
Outcome Measures: Implementation of a web-based Breast Cancer Collaborative Registry at the National Comprehensive Cancer Network (NCCN) centers;   Merger of data collected under the Adult Oncology Data Collection Study and the National Comprehensive Cancer Network Data Coordinating study at UNMC/NMC;   Standardization of clinical, environmental, socio-demographic, and family history data collected for breast cancer-related research and shared by the Eppley Breast Cancer Research Group collaborators
4 Recruiting Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)
Condition: Atypical Ductal Hyperplasia (ADH) of the Breast
Intervention:
Outcome Measures: Findings of palpable mass or imaging abnormality (increase in size or in the amount of calcifications);   Quality of life, patient satisfaction and costs between the two groups will be measured by the Functional Assessment of Chronic Illness Therapy (FACIT), specifically the FACT-G and the FACT-Es.
5 Unknown  Women At Risk: The High Risk Breast Cancer Program
Condition: Breast Cancer
Intervention:
Outcome Measure:
6 Recruiting Protocol for Women at Increased Risk of Developing Breast Cancer
Condition: Breast Cancer
Intervention:
Outcome Measure: Prediction of risk for developing breast cancer
7 Recruiting High-Risk Breast Duct Epithelium
Condition: Breast Cancer
Intervention:
Outcome Measure: 1. To determine the incidence and nature of cytologic changes inductal epithelial cells from the high risk breast, in specimenscollected by breast duct lavage, and to determine if these cytologicfindings are different from those of norm...
8 Not yet recruiting [18F]ISO-1 PET/CT in Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm
Intervention: Drug: [18F]ISO-1
Outcome Measures: Correlate [18F]ISO-1 uptake with qualitative immunohistochemical staining for the sigma 2 receptor, PGRMC1;   Evaluate the feasibility of using [18F]ISO-1 to image sigma-2 receptor binding in breast cancer;   Evaluate the safety of [18F]ISO-1;   Correlate [18F]ISO-1 uptake with sigma-2 receptor binding studies using [3H]RHM-1;   Correlate [18F]ISO-1 uptake with pathologic assays measuring cellular proliferation rates (e.g. Ki-67);   Correlate [18F]ISO-1 uptake a with multi-gene expression assay, validated to predict recurrence;   Correlate [18F]ISO-1 uptake with outcomes (e.g. time to recurrence, progression free survival and overall survival);   Test the association of [18F]ISO-1 uptake with phenotypic breast cancer subtypes (e.g. HER2+, TN, ER/PR+, etc.)
9 Recruiting Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia
Condition: Intraepithelial Carcinoma
Interventions: Drug: Tamoxifen;   Drug: placebo
Outcome Measures: Incidence of invasive breast cancer;   Incidence of other non-invasive breast disorders;   To determine CYP2D6 genotype
10 Recruiting Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Condition: Ductal Carcinoma in Situ
Intervention: Drug: SOM 230 / Pasireotide
Outcome Measures: Cell proliferation and apoptosis;   Effect of SOM 230 / pasireotide on tumor volume and tumor kinetics;   hyperglycemia
11 Recruiting Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Conditions: Adrenal Insufficiency;   Excess Androgen;   Congenital Adrenal Hyperplasia (CAH)
Interventions: Drug: Hydrocortisone (Solucortef);   Device: Insulin pump (Medtronic)
Outcome Measures: Percent of patients with 17-OH Progesterone levels equal or below 1,200 ng/dL at 8 a.m.;   Percent of patients with hypertensive BP measurements;   Body composition measured by DEXA;   Weight and BMI;   Insulin resistance measured by HOMA-IR;   Change in percent of patients with androstenedione & amp; testosterone within the normal range at 8 a.m.;   Fatigue and quality of life.
12 Unknown  Dose-escalation Study of Oral CX-4945
Conditions: Advanced Solid Tumors;   Breast Cancer;   Inflammatory Breast Cancer;   Castleman's Disease;   Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
Outcome Measures: Safety (Dose limiting toxicities, maximum tolerated dose);   Drug-related adverse events;   Pharmacokinetic and pharmacodynamic assessments;   Observe evidence of antitumor activity;   Establish the recommended Phase 2 dose
13 Recruiting Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
Conditions: BRCA1 Syndrome;   BRCA2 Syndrome;   Lynch Syndrome
Interventions: Procedure: PSA;   Other: IPSS questionnaire;   Procedure: DRE (Digital Rectal Examination );   Procedure: urine flow and residual;   Procedure: a multiparametric prostate MRI;   Procedure: trans-rectal ultra-sound guided prostate biopsy
Outcome Measures: Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers;   Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.

These studies may lead to new treatments and are adding insight into Breast Hyperplasia etiology and treatment.

A major focus of Breast Hyperplasia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Breast Hyperplasia